Results 161 to 170 of about 46,440 (207)

Enzyme-DNA Interactions Affect the Catalytic Inhibition of Mycobacterial Gyrases by Antibacterial Drugs. [PDF]

ACS Infect Dis
Armenia JF, Osheroff N.
europepmc   +1 more source

Hemorrhagic risk of concomitant direct oral anticoagulants and fluoroquinolones: integration of pharmacovigilance and therapeutic drug monitoring. [PDF]

Front Pharmacol
Xu J, Li YD, Han JP, Duan CY, Zhao FL, Shang ZY, Zhu Z, Hu ZH.   +7 more
europepmc   +1 more source

A Thorough QT Study to Assess the Effects of Milvexian on Cardiac Repolarization in Healthy Participants. [PDF]

Clin Pharmacol Drug Dev
Zannikos P, Park J, Dari A, Takhtoukh S, Levesque P, Plotnikov AN, Mitra A, Ajavon-Hartmann A, Merali S, Perez Ruixo JJ, Goyal N.   +10 more
europepmc   +1 more source

In vitro evolution provides insights into mechanisms of Mycoplasma genitalium resistance to moxifloxacin. [PDF]

J Antimicrob Chemother
Chua TP, Huaman JL, Danielewski J, Bradshaw CS, Machalek DA, McDonald MJ, Garland SM, Murray GL.   +7 more
europepmc   +1 more source

QT prolongation risk factors and a monitoring strategy in rifampicin-resistant tuberculosis: Findings from the STREAM Stage 2 trial. [PDF]

PLOS Glob Public Health
Hughes G, Frangou E, Bern H, Gurumurthy M, Tsogt B, Chiang CY, Nunn AJ, Meredith SK, Goodall RL, STREAM Trial Collaboration.   +9 more
europepmc   +1 more source

Evaluating treatment outcomes stratified by regimen among drug-resistant TB patients in Sierra Leone. [PDF]

Public Health Action
Koroma JA, Fofanah BD, Nair D, Kamau EM, Kamara IF, Sesay MA, Turay IS, Sesay N, Kanu F, Lahai WK, Kanu JS, Koroma AT, Fornah F, Seisay AL, Bailor SS, Harding R, Emezue S, Tefera GB, Ameh G, Mazzi M, Lakoh S, Mahmoud M.   +21 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Moxifloxacin

Drugs, 2012
exaly   +7 more sources